This Article Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by MURPHY, L. C. Articles by SUTHERLAND, R. L. Search for Related Content PubMed PubMed Citation Articles by MURPHY, L. C. Articles by SUTHERLAND, R. L.

Antitumor Activity of Clomiphene Analogs in Vitro: Relationship to Affinity for the Estrogen Receptor and Another High Affinity Antiestrogen-Binding Site

Ludwig Institute for Cancer Research (Sydney Branch), University of Sydney New South Wales 2006, Australia

The antitumor activity of three enclomiphene (trans-1- (p-β-diethylaminoethoxyphenyl)l,2-diphenyl-2-chloroethylene) analogs and the cis isomer zuclomiphene was investigated in MCF 7 human mammary carcinoma cellsin culture. Relative antitumor activity was compared with relative binding affinities (RBAs) for the nuclear estrogen receptor (R_E; estradiol = 100%) and a microsomal antiestrogen-binding site (AEBS; tamoxifen = 100%) measured in cell-free extracts from MCF 7 cells. Modifications in the structure of the diethylaminoethoxy side chain influenced affinity of both R_E and AEBS. Deethylation of the side chain (9599) reduced affinity for both sites by 65–70%, while a diethylaminoproproxy side chain (6866) resulted in a 3-fold increase in affinity for RE (enclomiphene = 2%; 6866 = 6%), but reduced the RBA for AEBS by 66% (enclomiphene = 140%; 6866 = 45%). Conversion of the ether linkage to an amine (10222) increased affinityfor R_E (10222 = 5%), but markedly reduced affinity for the AEBS (10222 = 15%).

All five compounds inhibited the growth of MCF 7 cells in culture, but with markedly different potencies. At low doses (0.25-1.0 µM), where the growth-inhibitory effects were reversedby estradiol (except in the case of zuclomiphene), the relative antitumor activity (6866 > 10222 > enclomiphene > 9599 > zuclomiphene) was in the same order as RBA for R_E. At higher doses (>2.5 µM), where the growth-inhibitory effects were unaffected or partially reversed by estradiol, the relative potencies of these compounds as antitumor agents changed. Zuclomiphene becamethe most active, while the potency of enclomiphene increased relative to 6866 and 10222 (zuclomiphene > enclomiphene > 6866 > 10222 > 9599). At these doses, estrogen-irreversible antitumor activity was unrelated to affinity for R_E, but showed some correlation with affinity for AEBS.

It is concluded that the major effect of these compounds on mammary carcinoma growth in vitro is an estrogen-reversible growth-inhibitory effect, the magnitude of whichis correlated with affinity for R_E. However, studies with zuclomiphene and estrogen-irreversible doses of enclomiphene and 6866 indicate that these antiestrogens also influence cell proliferation in vitro by mechanisms that probably do not involve R_E.

^* To whom requests for reprints should be addressed.

Received November 8, 1982.

This article has been cited by other articles:

				K. L. Terry, W. C. Willett, J. W. Rich-Edwards, and K. B. Michels A Prospective Study of Infertility Due to Ovulatory Disorders, Ovulation Induction, and Incidence of Breast Cancer Arch Intern Med, December 11, 2006; 166(22): 2484 - 2489. [Abstract] [Full Text] [PDF]